Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now how can you flip 018's if it's going subpenny?? Nervous? Someone riding free shares has no need to be nervous. Maybe I just want my profits in this play maximized.
CVSC Bouncing back??
Well that states it pretty loud and clear. I know one stockholder waiting with baited breath for those shares to go up for sale.
1.2 million in volume will do little to the share price....the new trading channel is .016 to .027 while they manipulate it
UBET Slow & Steady
VUOC Breaking out
so the 1.2million shares you hold in cert form will have to be shredded???
a stock under such tremendous accumulation cannot go sub penny just look at the CMF
Please do not make investment or trading decisions based on what you read from a stock board. Do your due diligence before buying any stock especially a penny stock. The stock market is where money is transferred from the impatient to the patient
and if the contract deal falls through then what?
if there is going to be a contract obviously it needs to be drawn up by a lawyer and the other party to the contract would obviously have their lawyer approve it also
VUOC +13.67%
she can't be painted unless they move the ask up which should happen in the next 15 minutes
I own SRSR too.....how dare Mr Buffet steal my signature!!!
charts don't lie.................this stock is being accumulated very heavily
Um that was from the last PR. So if reading a PR makes me an insider????????
Ok the CMF indicator pretty much shows this stock is under heavy accumulation.
My theory is looking pretty good.
The Chaikin Money Flow oscillator generates bullish signals by indicating that a security is under accumulation.
There are three factors that determine if a security is under accumulation. They also determine the strength of the accumulation.
The first and most obvious factor is whether the Chaikin Money Flow value is greater than zero? It is an indication of buying
pressure and accumulation when the indicator is positive.
The second factor is the duration of the reading, how long the oscillator has been positive. The longer the oscillator remains
above zero, the more evidence there is that the security is under sustained accumulation. Extended periods of accumulation or
buying pressure are bullish, and they indicate that sentiment towards the security remains positive.
The third factor is the intensity of the oscillator. Not only should the oscillator remain above zero, but it should also be
able to increase and attain a certain level. The more positive the reading is, the more evidence of buying pressure and accumulation.
This is usually a judgment call, based on prior levels for the oscillator, but a move above .10 would be significant enough to
warrant a bullish signal. A reading above .25 would be an indication of strong buying pressure. You should consider prior
levels of the indicator to be sure.
Please do not make investment or trading decisions based on what you read from a stock board. Do your due diligence before buying any stock especially a penny stock. The stock market is where money is transferred from the impatient to the patient
SOBM News +15%
Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
Investment Banking Firm Has Strong Background in Biotechnology
August 26, 2008: 01:15 PM EST
Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTCBB: SOBM) is pleased to announce that it has retained CB Capital Partners, Inc. as its financial advisor to evaluate strategic alternatives to maximize shareholder value.
"While we are extremely pleased with the results obtained from the work undertaken to date on our three marketed and seven pipeline drugs, four of which are moving towards commercial release, we feel this success is not yet represented in shareholder value," said Banjun Yang, Company President and CEO. "We have invested heavily in the respective successful development of our products; now we need assistance in developing our Company's share valuation."
These product developments include:
- The patented recombinant malaria vaccine candidate (PfCP2.9), for which Sinobiomed is now in discussions to initiate Phase IIb clinical trials.
- The Phase IIb clinical trials of the Company's patented anti-bleeding agent, recombinant Batroxobin (rBAT). Should the product proceed to Phase III clinical trials, it is expected that international governments and organizations would show significant interest. The Company has already received indications of interest from global pharmaceutical companies for joint development, marketing and production.
- Recent applications for a Chinese and an international patent for recombinant human kallikrein-1 (rhK1), and for a Chinese patent for an innovative recombinant multivalent tuberculosis vaccine.
- Continuing penetration of Chinese market of Sinobiomed's commercialized products, which treat a wide range of diseases including hepatitis B and hepatitis C. China is home to nearly one third of the world's hepatitis carriers.
"Collectively, these developments have substantially increased the value of Sinobiomed, which has seen a dramatic corresponding increase in market capitalization of nearly 200%. The Company believes, however, that its valuation remains well below the market capitalization and corresponding share price of above $3.00 per share. We further believe that our share price has been impacted by the overall decline in the Chinese capital markets."
"We have therefore retained CB Capital Partners as our financial advisor to assist in reviewing our strategic alternatives with the objective of maximizing shareholder value, and we look forward to working with them to ensure that all alternatives available to the Company are considered and evaluated to achieve that objective."
These alternatives may range from strategic alliances to assist in the development of its pipeline drugs to financing opportunities such as mergers, acquisitions, a sale of all or part of the business, or other initiatives considered to be in the best interests of the Company and its shareholders.
ABOUT CB CAPITAL PARTNERS
CB Capital Partners is a specialized investment banking firm, which focuses on creating value through customized financial advisory assignments including capital raises, debt placements, strategic and financial partnerships, and mergers and acquisitions transactions. The firm was founded in 2001 in order to bring innovative and value-added solutions to our clientele through a conservative and disciplined application of our diverse professional institutional investment banking talents. www.cbcapital.com.
ABOUT SINOBIOMED INC.
Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.
SINOBIOMED INC.
LANE 4705, NO. 58, NORTH YANG GAO RD.
PUDONG, NEW AREA SHANGHAI, 201206 CHINA
PHONE: 86-58993708 / FAX: 86-58993709
FORWARD LOOKING STATEMENTS This news release may include "forward-looking
statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contacts:
Sinobiomed Inc.
Investor Relations
(718) 502-8801 or Toll Free: 1-866-588-0829
Email: info@sinobiomed.com
Website: www.sinobiomed.com
SOBM News +15%
Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
Investment Banking Firm Has Strong Background in Biotechnology
August 26, 2008: 01:15 PM EST
Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTCBB: SOBM) is pleased to announce that it has retained CB Capital Partners, Inc. as its financial advisor to evaluate strategic alternatives to maximize shareholder value.
"While we are extremely pleased with the results obtained from the work undertaken to date on our three marketed and seven pipeline drugs, four of which are moving towards commercial release, we feel this success is not yet represented in shareholder value," said Banjun Yang, Company President and CEO. "We have invested heavily in the respective successful development of our products; now we need assistance in developing our Company's share valuation."
These product developments include:
- The patented recombinant malaria vaccine candidate (PfCP2.9), for which Sinobiomed is now in discussions to initiate Phase IIb clinical trials.
- The Phase IIb clinical trials of the Company's patented anti-bleeding agent, recombinant Batroxobin (rBAT). Should the product proceed to Phase III clinical trials, it is expected that international governments and organizations would show significant interest. The Company has already received indications of interest from global pharmaceutical companies for joint development, marketing and production.
- Recent applications for a Chinese and an international patent for recombinant human kallikrein-1 (rhK1), and for a Chinese patent for an innovative recombinant multivalent tuberculosis vaccine.
- Continuing penetration of Chinese market of Sinobiomed's commercialized products, which treat a wide range of diseases including hepatitis B and hepatitis C. China is home to nearly one third of the world's hepatitis carriers.
"Collectively, these developments have substantially increased the value of Sinobiomed, which has seen a dramatic corresponding increase in market capitalization of nearly 200%. The Company believes, however, that its valuation remains well below the market capitalization and corresponding share price of above $3.00 per share. We further believe that our share price has been impacted by the overall decline in the Chinese capital markets."
"We have therefore retained CB Capital Partners as our financial advisor to assist in reviewing our strategic alternatives with the objective of maximizing shareholder value, and we look forward to working with them to ensure that all alternatives available to the Company are considered and evaluated to achieve that objective."
These alternatives may range from strategic alliances to assist in the development of its pipeline drugs to financing opportunities such as mergers, acquisitions, a sale of all or part of the business, or other initiatives considered to be in the best interests of the Company and its shareholders.
ABOUT CB CAPITAL PARTNERS
CB Capital Partners is a specialized investment banking firm, which focuses on creating value through customized financial advisory assignments including capital raises, debt placements, strategic and financial partnerships, and mergers and acquisitions transactions. The firm was founded in 2001 in order to bring innovative and value-added solutions to our clientele through a conservative and disciplined application of our diverse professional institutional investment banking talents. www.cbcapital.com.
ABOUT SINOBIOMED INC.
Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.
SINOBIOMED INC.
LANE 4705, NO. 58, NORTH YANG GAO RD.
PUDONG, NEW AREA SHANGHAI, 201206 CHINA
PHONE: 86-58993708 / FAX: 86-58993709
FORWARD LOOKING STATEMENTS This news release may include "forward-looking
statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contacts:
Sinobiomed Inc.
Investor Relations
(718) 502-8801 or Toll Free: 1-866-588-0829
Email: info@sinobiomed.com
Website: www.sinobiomed.com
in a pink stock like UDHC the only verification comes from people that work at the company.....there are no 10Q's or other SEC filings. it's about as unverifiable as it is verifiable
No I do not have the right to post the name and a phone number of a company executive on a public board. Any shareholder can do the same DD I have done and obtain the information.
I will not post that on the board......sorry. However, I can tell you he has huge plans for SNV
yes I have verified it with the new head of sales for SNV
The company has also received an extraordinary amount of calls and e-mails regarding the ongoing contract negotiations regarding the previously announced deal to supply 1000 day care centers with security surveillance, at this time the company can only say that negotiations are ongoing and the company anticipates a positive result
fake contract news? what proof do you have it is fake?
I have not spoken to clayton since this time last week.
It must depened on whether you have a cash account or a margin account. I know I can't place market orders and my account is a margin account.
market order? Etrade does not allow market orders on pinks
so now do you believe us? we've been talking about this manipulation for months
IMHO the lawyers agreed the TA is at fault and they agreed to allow the TA to buy 10 million shares on the open market that will be retired once they buy is complete. I also believe this was all done without clayton's knowledge
if anyone can disprove this please do so
manipulation at its best
i agree and they are taking it down hard right now.......desperation
yep anotherwinninigtrade.com amd quality stocks
+22.22% now....it's being highly touted
BSTI +16.67%
the garbage is +16.67% in the first hour
Agreed.............real news is needed on the day care contract and the divvy screwup......
many shareholders would be happy with that
gotcha..............that's much clearer
just scanning for some undervalued prospects.........
You lost me on that one......how can a one month old public company have 15 months of chart data???
Please do not make investment or trading decisions based on what you read from a stock board. Do your due diligence before buying any stock especially a penny stock. The stock market is where money is transferred from the impatient to the patient
Agreed...........the days of falsely holding this stock down are soon coming to an end
WWE News
WWE(R) SmackDown(R) vs. Raw(R) 2008 Reaches "Greatest Hits" Sales Milestone for the PlayStation(R)2 Computer Entertainment System and PSP(R) (PlayStation(R)Portable) System
By BusinessWire
AGOURA HILLS, Calif., BUSINESS WIRE -- THQ Inc. (NASDAQ:THQI) and JAKKS Pacific, Inc. (NASDAQ:JAKK) today announced that WWE(R) SmackDown(R) vs. Raw(R) 2008, the ninth release from the leading fighting videogame franchise, has joined Sony's "Greatest Hits" collection for the PlayStation(R)2 computer entertainment system and PSP(R) (PlayStation(R)Portable) system. Both versions of the videogame originally launched in November 2007 and are now available for the suggested retail price of $19.99.
"Reaching 'Greatest Hits' status is a huge honor that speaks to the tremendous SmackDown vs. Raw fan base," said Scott Guthrie, executive vice president, publishing, THQ. "We look forward to delivering WWE SmackDown vs. Raw 2009 on seven platforms this fall, including the Xbox 360(R) video game and entertainment system from Microsoft, PLAYSTATION(R)3 computer entertainment system, PlayStation(R)2 computer entertainment system, PSP(R) (PlayStation(R)Portable) system, Wii(TM) videogame console, Nintendo DS(TM) and mobile devices."
"The WWE SmackDown vs. Raw legacy continues on through the incredibly loyal fans that master each new version," said Nelo Lucich, senior vice president of interactive, JAKKS Pacific. "With its 'Greatest Hits' status and through a reduced price point, we can share this virtual sports entertainment experience with an even more expansive audience."
About WWE SmackDown vs. Raw 2008
WWE SmackDown vs. Raw 2008 for the PlayStation 2 system and PSP system lets players take the fight into their own hands with the debut of eight Superstar Fighting Styles. Each fighting style has its own unique strategy with exclusive moves and abilities. A brand new Struggle Submission System gives players intuitive and natural control over their WWE Superstars using the analog sticks. Realism and strategy are at the forefront, as players can now control the amount of pressure they apply. WWE 24/7 Mode, which combines the popular Season and General Manager modes, embraces the intensity of the Superstar lifestyle. Multiple character development options, stat tracking and career goals guide players toward the ultimate achievement of becoming a WWE Legend. In addition, WWE SmackDown vs. Raw 2008 includes numerous fan-requested updates, including new rosters, more environmental hotspots, improved out-of-ring action and much more.
More information about WWE SmackDown vs. Raw 2008 can be found at www.smackdownvsraw.com and www.thq.com.
About World Wrestling Entertainment, Inc.
Additional information on World Wrestling Entertainment Inc. (NYSE:WWE) can be found at wwe.com and corporate.wwe.com. For information on our global activities, go to http://www.wwe.com/worldwide/.
About THQ Inc.
THQ Inc. (NASDAQ:THQI) is a leading worldwide developer and publisher of interactive entertainment software. The company develops its products for all popular game systems, personal computers and wireless devices. Headquartered in Los Angeles County, California, THQ sells product through its global network of offices located throughout North America, Europe and Asia Pacific. More information about THQ and its products may be found at www.thq.com. THQ and the THQ logo are trademarks and/or registered trademarks of THQ Inc.
About JAKKS Pacific, Inc.
JAKKS Pacific, Inc. (NASDAQ:JAKK) is a multi-brand company that designs and markets a broad range of toys and consumer products. The product categories include: Action Figures, Art Activity Kits, Stationery, Writing Instruments, Performance Kites, Water Toys, Sports Activity Toys, Vehicles, Infant/Pre-School, Plush, Construction Toys, Electronics, Dolls, Dress-Up, Role Play, and Pet Toys and Accessories. The products are sold under various brand names including JAKKS Pacific(R), Play Along(R), Flying Colors(R), Creative Designs International(TM), Road Champs(R), Child Guidance(R), Pentech(R), Trendmasters(R), Toymax(R), Funnoodle(R), Go Fly a Kite(R), Color Workshop(R), JAKKS Pets(TM) and Plug It In & Play TV Games(TM). JAKKS and THQ Inc. participate in a joint venture that has worldwide rights to publish and market World Wrestling Entertainment video games. For further information, visit www.jakks.com.
Trademarks: All WWE programming, talent names, images, likenesses, slogans, wrestling moves, trademarks, copyrights and logos are the exclusive property of World Wrestling Entertainment, Inc. and its subsidiaries. All other trademarks, logos and copyrights are the property of their respective owners.
Microsoft, Xbox, Xbox 360, Xbox Live, the Xbox logos, and the Xbox Live logo are either registered trademarks or trademarks of Microsoft Corporation in the U.S. and/or other countries.
"PlayStation," "PLAYSTATION," "PS" Family logo and "PSP" are registered trademarks of Sony Computer Entertainment Inc. PSP(R) system - Memory Stick Duo(TM) may be required (sold separately).
Wii and Nintendo DS are trademarks of Nintendo.
The statements contained in this press release that are not historical facts may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the business of THQ Inc. and its subsidiaries (collectively referred to as "THQ"), including, but not limited to, expectations and projections related to the WWE SmackDown vs. Raw 2008 video game, and are based upon management's current beliefs and certain assumptions made by management. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, business, competitive, economic, legal, political and technological factors affecting our industry, operations, markets, products or pricing. Readers should carefully review the risk factors and the information that could materially affect THQ's financial results, described in other documents that THQ files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal period ended March 31, 2008, and particularly the discussion of risk factors set forth therein. Unless otherwise required by law, THQ disclaims any obligation to update its view on any such risks or uncertainties or to revise or publicly release the results of any revision to these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
This press release may contain forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) that are based on current expectations, estimates and projections about JAKKS Pacific's business based partly on assumptions made by its management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such statements due to numerous factors, including, but not limited to, those described above, changes in demand for JAKKS' products, product mix, the timing of customer orders and deliveries, the impact of competitive products and pricing, and difficulties with integrating acquired businesses. The forward-looking statements contained herein speak only as of the date on which they are made, and JAKKS undertakes no obligation to update any of them to reflect events or circumstances after the date of this release.
Contacts:
THQ/Media Relations Jaime Jensen,
818-871-5111 jaime.jensen@thq.com or THQ/Investor Relations Julie MacMedan,
818-871-5125 investor@thq.com or JAKKS Pacific/Media Relations Genna Rosenberg,
310-455-6235 gennar@jakks.net or World Wrestling Entertainment,
Inc. Kevin Hennessy,
203-352-8657 kevin.hennessy@wwecorp.com
Copyright Business Wire 2008. All Rights Reserved
BSTI